For specialist prescribers and clinical pharmacists making formulation choices for cannabis-based products for medicinal use (CBPMs). Formulation is not a packaging decision. It determines onset, duration, dosing precision, drug-interaction potential and the realistic adherence profile a patient can achieve. This piece sets out what the pharmacokinetic literature supports across the main CBPM dosage forms and where the clinical trade-offs sit.
Why formulation choice is a clinical decision
The same THC and CBD content can produce markedly different clinical effects depending on the route of administration. Onset varies from minutes (inhaled) to hours (oral); peak plasma concentration varies by an order of magnitude; bioavailability ranges from below 10% (oral) to around 30% (inhaled); and the predictability of dosing varies even more widely. Selecting the wrong formulation for the indication is one of the most common reasons a CBPM trial fails to demonstrate benefit, and one of the most common reasons it produces avoidable adverse effects.
The clinical question is not “which formulation is best?” but “which formulation matches this patient’s symptom pattern, manual dexterity, adherence profile, drug-interaction profile and prior experience?”
Vaporised cannabis flower
Pharmacokinetics
Inhaled THC reaches the systemic circulation within seconds of the first breath. Peak plasma concentrations are achieved within 3 to 10 minutes. Bioavailability ranges from approximately 10% to 35% depending on inhalation technique — puff duration, breath-hold, depth and the vaporiser device itself — with substantial inter- and intra-patient variability. Vaporisation produces pharmacokinetics broadly comparable to combustion but with a cleaner inhalate and, in head-to-head studies, similar or marginally higher serum THC concentrations at equivalent doses. Duration of effect is typically 2 to 4 hours. Lucas and colleagues’ 2018 review in the British Journal of Clinical Pharmacology remains a useful summary for clinicians of the comparative pharmacokinetics across routes.
Clinical fit
Fast onset and short duration make vaporised flower suited to breakthrough symptoms — spasms, breakthrough pain, paroxysmal nausea, sleep-onset insomnia — where the patient needs to titrate effect against immediate experience. The same properties make it ill-suited for steady symptom control across a 24-hour cycle without multiple administrations.
Dosing precision challenges
Dosing precision is the principal weakness. Even with a calibrated medical vaporiser, the dose actually delivered depends on the patient’s inhalation profile. Two patients drawing from the same product at the same temperature receive different doses. Patients with respiratory disease, cognitive impairment, or significant frailty may not achieve reproducible technique. Standardised medical-grade vaporisers (e.g. Mighty Medic, Volcano Medic) and a structured patient education session improve consistency but do not eliminate variability.
Age and comorbidity considerations
Inhaled CBPMs are generally not appropriate in patients with active or unstable respiratory disease, recent pneumothorax, or significant cardiovascular instability. They are typically avoided in adolescents outside very specific specialist contexts. In older patients, vaporiser ergonomics and dexterity may limit usability; small studies and registry data suggest older patients more often gravitate to oils.
Sublingual and oromucosal oils
Pharmacokinetics
Sublingual and oromucosal oils sit between inhaled and oral routes. A proportion of the dose is absorbed across the oral mucosa, entering the systemic circulation directly and bypassing first-pass hepatic metabolism. The remainder is swallowed and undergoes oral absorption with significant first-pass effect. Onset is typically 15 to 45 minutes; peak concentration at 1 to 3 hours; duration 6 to 8 hours. Bioavailability is intermediate (estimates vary, often cited around 20-30% but with wide variance) and is materially affected by how long the patient holds the oil under the tongue before swallowing.
Clinical fit
Oils are the workhorse formulation for steady symptomatic control — neuropathic pain, anxiety, sleep maintenance, spasticity — where smoothed plasma concentrations are preferable to the peaks and troughs of inhaled dosing. They allow precise mg-level dosing via a graduated pipette, which is the most useful feature of the format for titration.
Dosing reproducibility
Dosing reproducibility is the format’s main strength. The dropper delivers a known mg dose per drop or mL. Patient technique still matters — holding the oil sublingually for 60 to 90 seconds versus swallowing immediately materially changes the absorption profile — but the variance is far narrower than with inhalation. Counsel patients explicitly on the hold time; a high proportion will swallow immediately if not told otherwise.
Food effects
Cannabinoids are highly lipophilic. The proportion of an oral oil dose absorbed via the GI tract is meaningfully increased when taken with food, particularly a high-fat meal. This is an underappreciated source of dose variability in patients whose meal timing is inconsistent. For predictable titration, a standardised relationship between dose and food intake (consistently with food, or consistently fasted) is more important than which one is chosen.
Softgels and capsules
Pharmacokinetics
Oral capsules bypass the oromucosal absorption phase entirely. Onset is 60 to 120 minutes; peak concentration at 2 to 4 hours; duration 6 to 10 hours. Oral bioavailability of THC and CBD is low — typically cited at 6-20% — and shows substantial inter-patient variability driven by first-pass metabolism, food effects and gut transit. The proportional pharmacokinetic gap between oils and capsules is smaller than it appears, because the swallowed proportion of an oil dose behaves like a capsule dose.
Clinical fit
Capsules are appropriate where dose-per-administration is well-defined, adherence at a fixed unit dose is preferable to titration-by-drop, and patients prefer a discreet, neutral-tasting format. They are particularly useful in workplace adherence contexts and in patients with strong taste aversion to oils.
Limitations
The fixed unit dose limits fine titration. Capsule formats typically come in 5, 10 or 25 mg increments of total cannabinoid content; intermediate doses require alternating quantities or co-administration with oils. The food effect is more pronounced than with oils because none of the dose bypasses the GI tract.
Patches and topicals
Where the evidence sits
Transdermal CBD and THC patches are commercially available in some markets, including in the UK private-prescribing space, but the clinical evidence base for systemic delivery via patch is sparse. Cannabinoid permeation across intact skin is limited by the lipophilicity profile, and reliable transdermal systemic dosing has been technically difficult to achieve. Topical preparations (creams, balms) have a more coherent local-effect rationale, primarily for musculoskeletal and dermatological symptom relief, but systemic exposure is minimal and the local clinical evidence remains observational.
Clinical use
Topicals are reasonable adjuncts in localised pain or pruritus where the patient prefers a non-systemic approach, particularly where comorbidity or interaction risk make systemic dosing problematic. They should not be expected to substitute for systemic CBPMs in indications that require central pharmacological action.
Switching between formulations
Inter-formulation switching is one of the highest-risk transitions in CBPM management because the mg-to-mg equivalence is not linear. A patient stabilised on inhaled flower with 60 mg of THC daily cannot simply be transitioned to 60 mg of oral THC; the lower oral bioavailability would produce sub-therapeutic effect, while a naive uplift to compensate could produce overshoot once accumulation occurs over the longer oral half-life. As a working principle:
- Inhaled to oral. Expect the equivalent steady-state effect to require a different daily total (often higher) and a longer time to reach steady state (typically 3-7 days versus same-day).
- Oral to inhaled. Expect more rapid effect onset and a more pronounced peak. Reduce per-administration dose to manage acute exposure.
- Oil to capsule (or vice versa). Closer to equivalent but not identical. Account for the sublingual fraction of the oil dose.
Document the switch carefully and arrange earlier review. The biggest source of adverse events around switching is patients self-correcting in either direction between formal reviews.
Storage and stability
CBPMs are subject to thermal and oxidative degradation, with THC oxidising slowly to CBN under exposure to light, heat and air. Flower stored above room temperature or in poorly sealed packaging loses potency over months and develops a higher CBN ratio. Oils degrade more slowly but are similarly sensitive to light. Manufacturer storage instructions are not a formality and should be reinforced at counselling. For controlled-drug storage in pharmacy and clinic settings, the practical implications for stock management are covered in our piece on CBPM supply chain considerations.
Titration approach by formulation
- Vaporised flower: single-inhalation titration. Patient takes one inhalation, waits 10-15 minutes, assesses effect, repeats if needed. Daily ceiling defined by total dispensed quantity. This is the most patient-driven titration model and requires capable, motivated patients.
- Oils: incremental mg-based titration. Typical starting points for THC-containing oils are well below 5 mg/day THC, increased by small increments every 3-7 days against symptom response. CBD-only oils can titrate more rapidly given the gentler acute profile.
- Capsules: unit-dose titration. Increase by one unit at appropriate intervals. The unit-dose constraint argues against capsules as the initial titration format in opioid-experienced or cannabinoid-naive patients.
Adherence patterns in observational data
UK and international registry data describe a recognisable pattern: a meaningful proportion of patients use more than one formulation concurrently, typically a steady oral background plus inhaled rescue for breakthrough symptoms. Single-formulation regimens are more common in older patients, in palliative settings and in indications dominated by steady-state symptoms (spasticity, generalised anxiety). Adherence at three months is generally good in published registry cohorts but skewed by the motivated, self-pay private population from which much of the data derives. Clinicians should not assume similar adherence in patients who reach CBPMs via a different route.
Counselling points to brief patients on
- The first dose is not the dose. Effect at 7 days may be substantially different from effect at day 1, particularly with oils and capsules where accumulation occurs.
- Consistency with food matters. Choose with-food or fasted and keep it the same.
- Driving and operating machinery: covered formally in our forthcoming drug-interactions and contraindications piece, but should be addressed at first dispense and re-addressed at every dose change.
- Storage: cool, dark, sealed. Discard at the labelled expiry; cannabinoid content drops gradually thereafter.
- Concurrent alcohol and sedative use produces additive impairment that is not always intuitive at modest doses.
The bottom line for formulation choice
Choose the formulation that fits the symptom pattern and the patient, then optimise titration within that format before switching. The two most common avoidable mistakes are starting with inhaled flower in a patient who needs steady-state coverage, and starting with oils in a patient whose dominant symptom is breakthrough. Neither error is irrecoverable, but both can sour a patient on CBPM therapy before the right formulation has been tried.
For broader pathway context, see our overview of prescribing CBPMs on the UK specialist pathway. For trade and dispensing partners, see our Distributors page.
About MUZO Health
MUZO Health was created to raise the standard of cannabis-based medicines in the UK, with a focus on quality, consistency and clinical integrity. Our mission is to support clinicians, empower patients and help move cannabis medicine forward responsibly, transparently and without compromise. Learn more about MUZO Health.